JOURNAL ONKOLOGIE – STUDIE

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Studien-Informationen Einschlusskriterien Studien-Rationale Studien-Arme Geprüfte Regime

Rekrutierend

NCT-Nummer:
NCT04123418

Studienbeginn:
Dezember 2019

Letztes Update:
02.06.2021

Wirkstoff:
WVT078, WHG626

Indikation (Clinical Trials):
Multiple Myeloma, Neoplasms, Plasma Cell

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 1

Sponsor:
Novartis Pharmaceuticals

Collaborator:
-

Kontakt

Novartis Pharmaceuticals
Kontakt:
Phone: 1-888-669-6682
E-Mail: novartis.email@novartis.com» Kontaktdaten anzeigen

Novartis Pharmaceuticals
Kontakt:
Phone: +41613241111
» Kontaktdaten anzeigen

Studienlocations
(3 von 11)

Novartis Investigative Site
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps

Novartis Investigative Site
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps

Emory University School of Medicine
30322 Atlanta
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Ifeyinwa Kanayo Benyeogor
Phone: +1 404 778 4189
E-Mail: ibenyeo@emory.edu» Ansprechpartner anzeigen

Medical College of Wisconsin
53226 Milwaukee
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Althea B Thomas
Phone: 414-805-5249
E-Mail: Athomas@mcw.edu» Ansprechpartner anzeigen

Novartis Investigative Site
3181 Prahran
AustraliaRekrutierend» Google-Maps

Novartis Investigative Site
6423906 Tel Aviv
IsraelRekrutierend» Google-Maps

Novartis Investigative Site
20162 Milano
ItalyRekrutierend» Google-Maps

Novartis Investigative Site
113-8677 Bunkyo ku
JapanRekrutierend» Google-Maps

Novartis Investigative Site
NO 0450 Oslo
NorwayRekrutierend» Google-Maps

Novartis Investigative Site
39008 Santander
SpainRekrutierend» Google-Maps

Novartis Investigative Site
08041 Barcelona
SpainRekrutierend» Google-Maps

Alle anzeigen

Studien-Informationen

Detailed Description:

This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to

characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078

alone and in combination with WHG626 in subjects with MM who have received two or more

standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38

agent (if available) and are relapsed and/or refractory to or intolerant of each regimen. In

addition, this study will assess preliminary anti-MM response of and characterize the

pharmacokinetics and immunogenicity of WVT078 alone and in combination with WHG626. The

results of this study will inform the future development of WVT078 alone and in combination

with WHG626 as a treatment for relapsed and/or refractory MM.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Subjects who are relapsed and/or refractory to two or more regimens including an IMID,

proteasome inhibitor, and an anti-CD38 agent (if available)

Exclusion Criteria:

- Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or

any immunosuppressive therapy within 7 days of first dose of study treatment

- Malignant disease other than being treated on this study

- Active known or suspected autoimmune disease

- Impaired cardiac function or clinically significant cardiac disease

- Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy

within 14 days or 5 half-lives whichever is shorter

- Active central nervous system involvement by malignancy or presence of symptomatic CNS

metasteses

Studien-Rationale

Primary outcome:

1. Incidence of dose limiting toxicity (DLTs) in Cycle 1 (Time Frame - 28 days (first cycle)):
To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM

2. Frequency of dose interruptions (Time Frame - Up to 28 months):
To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM

3. Frequency of discontinuations (Time Frame - up to 28 months):
To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM

4. Frequency of dose reductions (Time Frame - up to 28 months):
To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM

5. Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, ECGs, and CRS/immune-mediated reactions (Time Frame - Up to 31 months):
To characterize the safety, tolerability, and determine the recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with relapsed and/or refractory MM

Secondary outcome:

1. Best Overall Response (BOR) (Time Frame - Up to 36 months):
Response assessment per International Myeloma Working Group (IMWG) criteria

2. Duration of Response (DOR) (Time Frame - Up to 36 months):
Response assessment per International Myeloma Working Group (IMWG) criteria

3. Progresson Free Survival (PFS) (Time Frame - Up to 36 months):
Response assessment per International Myeloma Working Group (IMWG) criteria

4. AUC of WVT078 derived from serum concentrations (Time Frame - Up to 28 months)

5. Cmax of WVT078 derived from serum concentrations (Time Frame - Up to 28 months)

6. Cmin of WVT078 derived from serum concentrations (Time Frame - Up to 28 months)

7. Tmax of WVT078 derived from serum concentrations (Time Frame - Up to 28 months)

8. T1/2 of WVT078 derived from serum concentrations (Time Frame - Up to 28 months)

9. Concentration of WVT078 Anti Drug Antibodies (ADA) as measured in serum (Time Frame - Up to 28 months)

10. AUC of WHG626 derived from plasma concentrations (Time Frame - Up to 28 months)

11. Cmax of WHG626 derived from plasma concentrations (Time Frame - Up to 28 months)

12. Cmin of WHG626 derived from plasma concentrations (Time Frame - Up to 28 months)

13. Tmax of WHG626 derived from plasma concentrations (Time Frame - Up to 28 months)

14. T1/2 of WHG626 derived from plasma concentrations (Time Frame - Up to 28 months)

15. AUC of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations (Time Frame - Up to 28 months)

16. Cmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations (Time Frame - Up to 28 months)

17. Cmin of GWQ573 (the active metabolite of WHG626) devived from plasma concentrations (Time Frame - Up to 28 months)

18. Tmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations (Time Frame - Up to 28 months)

19. T1/2 of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations (Time Frame - Up to 28 months)

Studien-Arme

Experimental: WVT078 in Multiple Myeloma (MM) patients
Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
Experimental: WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients
Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)

Geprüfte Regime

WVT078:
WVT078 will be administered IV (intravenously) in a dose escalation schedule
WHG626:
WHG626 will be administered orally in a dose escalation schedule

Quelle: ClinicalTrials.gov

Das könnte Sie auch interessieren

Kinderkrebsnachsorge: Nachsorgepreis 2021 – Ausschreibung

Kinderkrebsnachsorge%3A+Nachsorgepreis+2021+%E2%80%93+Ausschreibung+ — ©fotomek - stock.adobe.com

Die Deutsche Kinderkrebsnachsorge – Stiftung für das chronisch kranke Kind vergibt 2021 zum 20. Mal den mit 10.000 Euro dotierten Nachsorgepreis. Mit dieser Auszeichnung werden sowohl wissenschaftliche als auch praktische zukunftsweisende Arbeiten, Projekte und Initiativen der stationären und ambulanten Familienorientierten Betreuung und Nachsorge gefördert.

Was hilft Kindern mit Krebs und deren Eltern?

Wenn ein Kind an Krebs erkrankt, verändert sich in einem Augenblick das gesamte Leben der Familie – Gefühle, Gedanken, der Alltag. Für die Eltern krebskranker Kinder ist es eine große Belastung, sich in der neuen Lebenssituation mit den Unsicherheiten und Verlustängsten zurechtzufinden. In dieser schwierigen Situation gibt es viele unterstützende Angebote. Das ONKO-Internetportal stellte in seinem...

Den Krebs überlebt, aber trotzdem nicht gesund

Den+Krebs+%C3%BCberlebt%2C+aber+trotzdem+nicht+gesund — © Kittiphan - stock.adobe.com

Immer mehr Menschen überstehen ihre Krebserkrankung. Sie werden geheilt oder können mit der Krankheit langfristig leben. Doch der Krebs selbst, wie auch seine Behandlung fordern oft ihren Tribut. Viele Betroffene leiden noch Jahre und Jahrzehnte später unter körperlichen, seelischen und sozialen Folgen.

Krebs kennt keine Grenzen – Bekämpfung erfordert interkulturelle Zusammenarbeit

Krebs+kennt+keine+Grenzen+%E2%80%93+Bek%C3%A4mpfung+erfordert+interkulturelle+Zusammenarbeit — © Fotolia / Alexey Popov

Die gemeinnützige Forschungsförderungsgesellschaft für Komplementärmedizin e.V. bemüht sich um Erhaltung, Förderung sowie die grenzübergreifende Verbreitung naturheilkundlichen Wissens – denn Erkrankungen machen sich nichts aus Staatsgrenzen, Sprachbarrieren oder politischen Differenzen.

Zielgerichtete Brustkrebstherapie ist erfolgreich

Brustkrebs kann jede Frau treffen. Eine von acht Frauen wird im Laufe ihres Lebens mit der Diagnose konfrontiert - allein in Deutschland sind das 72.000 Frauen im Jahr. Doch dank innovativer Forschung und Entwicklung wurden gerade in der Behandlung von Brustkrebs in den vergangenen Jahren große Fortschritte erreicht. Heute sind zielgerichtete Medikamente verfügbar, die die Überlebensaussichten von Frauen mit Brustkrebs...